knowledge -WSS

knowledge

author：comprehensive 2025-09-29 20:53:33 - browse：939

An advisory committee to the Food and Drug Administration will convene on Tuesday to evaluate the benefits of renal denervation, a one-time surgical procedure that works to reduce blood pressure. The promise — and the potential market — is enormous, but the data on how well the procedure works remains contentious.

The committee will evaluate data from two companies vying for market approval: ReCor Medical, a startup owned by Japanese company Otsuka Medical Devices, and device giant Medtronic, both of which have made surgical systems to treat hypertension.

Data from an analysis of three randomized clinical trials of ReCor Medical’s device showed a modest decrease in blood pressure after two months compared to a control group that received a placebo procedure. Medtronic’s late-stage trial showed that renal denervation reduced hypertension when measuring blood pressure in the doctor’s office, but did not show a reduction in blood pressure when patients measured it at home over 24 hours. At-home blood pressure is considered the more accurate measure, as blood pressure levels tend to artificially rise with anxiety in the clinic. Neither study presented serious safety concerns.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Why doctors need education on FDA device approval process

hotspot

WSS

Gene therapy has helped boys walk. Can scientists keep it that way?

Paxlovid study fails to answer questions over benefit for broader groups

The story of mRNA: From a loose idea to a tool that may help curb Covid

New guidelines on severe brain injury complicate already difficult decisions

Eli Lilly, Pfizer, and others want in on the online prescription market

Dewpoint Therapeutics lays off staff after losing partnerships

hotspot

knowledge

hotspot

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

EU regulator recommends expanding Mounjaro approval to obesity

BioMarin wins approval for gene therapy to treat hemophilia A

Gene therapy has helped boys walk. Can scientists keep it that way?

Affirmative action in medical school literally saved lives

Dewpoint Therapeutics lays off staff after losing partnerships

Moonlake's readout produced a cash windfall. Risks remain

The science behind Janet Jackson's pregnancy at 49

Virginia high school admissions case could be legal follow

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

hotspot

What is the Wagner Group? The 'brutal' Russian military unit in Ukraine

Why drug prescriptions should include diagnoses

Cloning humans is technically possible. It's curious no one has tried

Independent physicians launch a new lobbying group

Eli Lilly, Pfizer, and others want in on the online prescription market

The story of mRNA: From a loose idea to a tool that may help curb Covid

focus

explore

hotspot

focus